Is Alpha Tau Medical Ltd (DRTS) a Buy, Sell, or Hold?
NASDAQ : DRTS
Alpha Tau Medical Ltd
$14.27 USD
$0.67 (4.93%)
- Volume
- 881.05K
- Average Volume
- 747.8K
- Market Capitalization
- $1.29B
- P/E Ratio
- -21.30
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $14.30
- Year Low
- $3.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.79
Company Overview
NASDAQ
Uzi Sofer
Medical - Equipment & Services
Healthcare
DRTS
121
IL
USD
Liquidity Metrics
0.21
7.79
7.79
0.81
0.00
Sales & Valuation
-$
0.00
18.46
-39.35
-0.37
Profitability
-$0.53
-$42.63M
0.00%
0.00%
-73.23%
-52.29%
P/E Metrics
-21.30
0.60
0.60
Analyst Price Target & Rating
$16.00
$17.00
$8.00
1/5
6 Analysts
-10.81%
Financial Health Scores
15.32
2/9
$70.9M
$108.77M
$39.42M
-$46.71M
Key Metrics (TTM)
$1.23B
0.00
-27.47
7.79
-73.23%
-46.51%
-4.66%
-2.67%
0 days
Company Executives
| Name | Title |
|---|---|
| Rebecca Becker | Vice President of legal |
| Yael Zeiger | Corporate Controller |
| Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board |
| Robert Den | Chief Medical Officer & Member of Scientific Advisory Board |
| Amnon Gat | Chief Operations Officer |
| Raphi Levy | Chief Financial Officer |
| Ronen Segal | Chief Technology Officer |
| Uzi Sofer | Chief Executive Officer & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Alpha Tau Medical Ltd (NASDAQ:DRTS) Stock
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel. ...
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
2026-08-10 08:00:00
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.
2026-07-21 08:30:00
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorably with historical benchmarks for pembrolizumab monotherapy in this setting of 12.3 months and 3.2 months, respectively - - No Alpha DaRT-associated serious adverse events were observed; the only two Alpha DaRT-associated adverse events were Grade 1 (mild) - - Results build on foundation of Alpha DaRT monotherapy data in head and neck cancer, and lend support to Alpha Tau's ongoing clinical strategy exploring the combination approach, which the Company continues to discuss with the U.S. FDA - - Trial recruitment is now complete, having met the pre-specified success criterion of its Simon two-stage adaptive design: more than six patients responding to the treatment - JERUSALEM, July 21, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”) (Nasdaq: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), in which the combination produced a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients.
Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why
2026-07-19 04:01:47
Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) shares rose 7.1% on Friday. The company traded as high as $12.53 and last traded at $12.7280. 196,591 shares were traded during trading, a decline of 67% from the average daily volume of 591,564 shares. The stock had previously closed at $11.88. Analysts Set New
2026-07-15 08:30:00
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
New Strong Sell Stocks for July 7th
2026-07-07 09:36:09
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
New Strong Sell Stocks for July 2nd
2026-07-02 04:50:16
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
2026-06-25 12:00:00
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
2026-06-23 08:30:00
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Frequently Asked Questions
-
What is the current Alpha Tau Medical Ltd (DRTS) stock price?
-
Alpha Tau Medical Ltd(NASDAQ:DRTS) stock price is $14.27 in the last trading session. During the trading session, DRTS stock reached the peak price of $14.3 while $3 was the lowest point it dropped to. The percentage change in DRTS stock occurred in the recent session was 4.93% while the dollar amount for the price change in DRTS stock was $0.67.
-
DRTS's industry and sector of operation?
-
The NASDAQ listed DRTS is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector.
-
Who are the executives of DRTS?
-
Rebecca Becker | Vice President of legal
Yael Zeiger | Corporate Controller
Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board
Robert Den | Chief Medical Officer & Member of Scientific Advisory Board
Amnon Gat | Chief Operations Officer -
How many employees does DRTS have?
-
Number of DRTS employees currently stands at 121. DRTS operates from Kiryat HaMada St. 5, Jerusalem, JM 9777605, IL.
-
Link for DRTS official website?
-
Official Website of DRTS is: https://www.alphatau.com
-
How do I contact DRTS?
-
DRTS could be contacted at phone #972 3 577 4115 and can also be accessed through its website. DRTS operates from Kiryat HaMada St. 5, Jerusalem, JM 9777605, IL.
-
How many shares of DRTS are traded daily?
-
The average number of DRTS shares traded daily for last 3 months was 747.8K.
-
What is the market cap of DRTS currently?
-
The market value of DRTS currently stands at $1.29B with its latest stock price at $14.27